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A high-throughput multiplex bead suspension array was developed for the rapid subgenogrouping of EV71
strains, based on single nucleotide polymorphisms observed within the VP1 region with a high sensitivity as low
as 1 PFU. Of 33 viral isolates and 55 clinical samples, all EV71 strains were successfully detected and correctly
subgenogrouped.
Hand, foot, and mouth disease (HFMD) mainly afflicts chil-
dren and is characterized by fever and vesicles and ulcers on
the mouth, palms, limbs, and buttocks. Although several en-
teroviruses are etiologic agents of HFMD, neurologic compli-
cations such as aseptic meningitis, brainstem encephalitis, and
poliomyelitis-like paralysis have been associated with entero-
virus 71 (EV71) infection. Fatalities due to EV71 infection
have occurred during large outbreaks of HFMD in the Asia-
Pacific region since 1997. EV71 possesses a positive single-
stranded linear RNA genome, with four capsid proteins (VP1,
VP2, VP3, and VP4) present on the outermost part of the
nonenveloped virus (6, 11). Molecular phylogenetic analyses
based on EV71 VP1 sequences have classified EV71 strains
into three main genogroups, A, B, and C, which are further
classified into subgenogroups B1 to B5 and C1 to C5 (2–4, 11).
Although no direct association between the severe neuro-
logic complications of HFMD and different EV71 genetic lin-
eages has been established, subgenogrouping of EV71 is im-
portant for epidemiologic studies of the surveillance of both
endemic and epidemic HFMD and also facilitates further stud-
ies of EV71 virulence and evolution. However, subgenogroup-
ing of EV71 has been hitherto dependent on classical reverse
transcription (RT)-PCR and direct DNA sequencing, which
are relatively labor-intensive for processing large numbers of
samples during outbreaks. Therefore, with the ever-increasing
number of HFMD outbreaks, we developed a high-throughput
EV71 detection platform based on Luminex xTAG technology
(5) with rapid genogrouping capability that can be applied in
routine clinical diagnosis and that may be beneficial for epide-
miologic surveillance of EV71 infections.
Virus isolates or viral RNA representing nine EV71 sub-
genogroups were initially employed as reference strains to
develop the assay. However, for subgenogroups B1 and C3,
viral isolates could not be obtained. Thus, corresponding plas-
mids incorporating the full-length VP1 genes of strains 609-
AUS-74 and 009-KOR-00 were constructed using synthetic
DNA cloned into the pUC57 vector (GenScript, Piscataway,
NJ). Only viral RNA of strain MY104-9-SAR-97 (subgeno-
group B3) was obtained, and its VP1 gene was also cloned into
the pCR-XL-TOPO vector for ascertaining sensitivity. Thirty-
three other viral isolates from Japan, Malaysia, and Singapore
were tested for validation of the assay, with new VP1 nucleo-
tide sequences deposited in GenBank under accession num-
bers HQ285091 to HQ285109. A total of 55 clinical specimens
were also collected from suspected HFMD patients who pre-
sented at the National University Hospital mainly during the
2008 HFMD outbreak in Singapore (12). These samples were
tested by conventional and real-time RT-PCR, by DNA se-
quencing (8–10, 12), and also by the multiplex subgenogroup-
ing assay. This clinical study was approved by the Institutional
Review Board of the National University of Singapore (ap-
proval no. NUS-301).
Consensus primers were designed based on the VP1 region
of all EV71 subgenogroups. The 1.2-kb VP1 fragment was
amplified from each cDNA sample using the consensus prim-
ers, and amplicons were purified by ExoSAP-IT treatment
(Affymetrix, Santa Clara, CA) to remove excess nucleotides
and primers. Alignment of sequences showed that all EV71
subgenogroups (except C1) differed by only a single nucleotide
at different regions within VP1 (see Fig. S1 in the supplemental
material). Therefore, multiplex allele-specific primer extension
(ASPE), which differentiates gene sequences by only one nu-
cleotide difference at the 3 end and permits amplification only
of the perfectly complementary probe, was chosen instead of
the direct DNA hybridization Luminex assay. Initially, the lat-
ter was analyzed, but it suffered from very low specificity.
Specific ASPE probes were designed for 11 subgenogroups
based on the single nucleotide disparity located at the 3 end of
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each probe (see Table S1 in the supplemental material). A tag
sequence was incorporated at the 5 end of each probe to allow
hybridization to the anti-tag sequence of the corresponding
xTAG microspheres (Luminex, Austin, TX) as portrayed in
Fig. 1. Since there was no single nucleotide difference unique
for C1, we selected a nucleotide position that could distinguish
C1 and C3 from the other nine subgenogroups but whose
nucleotide polymorphism site was different from that of the C3
probe. The C1 probe was designed to thus identify both C1 and
C3, but these subgenogroups could be differentiated by the C3
probe reading. Hence, high readings of both C1 and C3 probes
indicated that the sample was from subgenogroup C3, whereas
a high reading only for C1 revealed a sample belonging to
subgenogroup C1. The multiplex ASPE reaction mix com-
prised 10 l of PCR product, 2 l of 10 ASPE buffer (20 mM
Tris-HCl, 50 mM KCl), 0.5 l of 50 mM MgCl2, 1 l of 500 nM
xTAG-ASPE primer mix, 1 l each of 100 M dATP, dGTP,
and dTTP, 0.25 l of 400 M biotin-dCTP, 0.15 l of Platinum
GenoTYPE Tsp DNA polymerase (5 U/l) (Invitrogen, Carls-
bad, CA), and water in a total volume of 20 l. The ASPE
reactions were incubated at 96°C for 2 min, subjected to 30
cycles each at 94°C for 0.5 min, 55°C for 1 min, and 72°C for 2
min, and held at 4°C until used. ASPE products were labeled
with biotin-dCTP and were hybridized with microspheres
through the tag and anti-tag nucleotide sequences. Streptavi-
din-phycoerythrin (SAPE) was added last for the detection of
biotin, and the whole microsphere-PCR complex passed
through the detection chamber of the Luminex reader (Lumi-
nex, Austin, TX). The readout was the median fluorescence
intensity (MFI) and is dependent on the number of viral copies
present. Relative rather than absolute readings were com-
pared; i.e., the highest sample-to-blank control ratio identified
the subgenogroup of the analyte in the sample. The cutoff
value (COV) specific for a particular subgenogroup was arbi-
trarily assigned as the ratio that was at least 10 times that of the
blank sample. Each sample assay was performed at least four
times, and the mean value was calculated. Virus isolates were
available for subgenogroups A, B2, B4, B5, C1, C2, C4, and C5,
and the assay sensitivity was based on the lowest number of
PFU detected (7). Samples corresponding to 1, 5, 20, 50, and
100 PFU were subjected to RNA extraction, RT-PCR, multi-
plex ASPE, and hybridization. However, viral isolates were not
available for three subgenogroups (B1, B3, and C3), and sen-
sitivity was determined by the lowest number of plasmid copies
detected (out of 1, 10, 100, and 1,000 copies analyzed).
For optimization of the system, reference strains represent-
ing the 11 subgenogroups of EV71 were tested with coxsack-
ievirus A16 (CA16) as a negative control, and all could be
detected by subgenogroup-specific probes. Nine probes yielded
average ratios that were at least 100 times that of the blank
control (Table 1). For probes B5 and C4, the ratios were
comparatively lower but still close to 100. These relatively
lower ratios may be explained by the lower GC content of B5
and C4 probes (48% and 40%, respectively) that culminates in
less efficient hybridization and linear amplification (1). Com-
pared to direct DNA sequencing of amplified products as the
benchmark, the results generated from our multiplex tech-
nique were consistent and reproducible. Validation with 33
additional viral isolates demonstrated that our assay could
specifically identify the subgenogroups of other EV71 strains
(see Table S2 in the supplemental material). In addition, by
testing 55 clinical specimens, we could reliably distinguish 11
FIG. 1. Schematic representation of the multiplex suspension array system for EV71 subgenogrouping. The VP1 region was amplified by
consensus primers, and the RT-PCR product was purified by ExoSAP-IT. ASPE was performed, and only perfectly complementary strands would
be amplified. The ASPE products were labeled using biotin-dCTP (black stars), and hybridized to their complementary anti-tag oligonucleotide
sequences on the beads or microspheres. The complex was subjected to the Luminex reader and was identified by both lasers and streptavidin-
phycoerythrin (SAPE).
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EV71-positive samples from 44 EV71-negative samples by our
assay, with the subgenogrouping data being congruent with
DNA sequencing (Table 1). One drawback is that a definite
conclusion cannot be made that our assay can be used for the
identification of all 11 EV71 subgenogroups. Although quite a
number of clinical samples and isolates were correctly identi-
fied for subgenogroups B5, C1, and C2, more samples belong-
ing to the other subgenogroups should be tested in the future.
Real-time RT-PCR can detect as few as 3 viral RNA copies
and 10 plasmid copies (9, 10). Therefore, various amounts of
the subgenogroups were subjected to analysis by our assay, and
the sensitivity varied among the subgenogroup-specific probes
(Table 2). With our multiplex assay, at least 100 PFU could be
detected for all subgenogroups by plaque assay. Amounts as
small as 1 PFU of C1, C2, and C5 and 5 PFU of A, B2, and B5
were detectable. Surprisingly, B4 could be detected only from
100 PFU, despite its relatively high reading in the specificity
testing. The B4 probe has a GC percentage of 55%, with a







EV71 subgenogroup-specific probe: Scrambled
probe
controlbA B1 B2 B3 B4 B5 C1 C2 C3 C4 C5
Reference strains
BrCr 324.4 1.8 3.3 0.9 0.8 1.1 1.5 3.7 0.8 0.8 1.3 0.4 A
2609-AUS-74 7.7 764.9 199.3 8.2 10.1 10.7 8.4 5.5 4.9 3.1 1.5 0.5 B1
7423/MS/87 1.7 18.9 833.1 1.5 1.5 2.6 2.4 1.4 1.6 1.0 1.1 0.4 B2
MY104-9-SAR-97 1.6 13.5 74.3 561.5 1.9 4.0 2.1 1.6 1.2 1.1 1.1 0.9 B3
5865/SIN/000009 2.3 13.5 49.4 2.1 390.9 5.6 3.7 1.7 1.6 1.5 1.1 0.5 B4
2933-Yamagata-03 2.3 4.6 54.9 1.5 1.8 97.7 2.0 1.5 1.1 1.0 1.2 0.4 B5
S10862-SAR-98 2.3 2.6 1.6 1.2 0.9 1.5 476.1 10.8 1.0 1.0 2.4 0.0 C1
Y97-1188 2.5 4.8 2.3 1.1 2.3 3.1 19.9 265.4 1.4 0.9 5.0 0.5 C2
009-KOR-00 12.2 12.9 5.3 2.3 3.8 8.1 998.4 2.2 229.6 2.6 4.3 0.8 C3
75-Yamagata-03 2.6 5.3 2.3 35.5 2.9 4.2 5.7 8.7 1.4 91.7 1.9 0.8 C4
3437/SIN/06 2.9 70.6 4.0 1.8 2.9 2.7 41.5 7.7 3.1 1.6 176.4 0.5 C5
CA16 control 2.5 0.6 0.0 0.3 1.7 0.0 0.0 1.2 0.6 0.1 1.3 0.6 CA16
Clinical specimens from 2008
outbreak
NUH0029/SIN/08 1.6 8.3 10.1 1.5 96.1 1.0 0.0 1.1 7.6 2.9 0.7 1.0 B4
NUH0012/SIN/08 4.0 1.0 2.3 3.0 1.0 86.7 1.7 0.5 0.8 0.3 0.9 0.8 B5
NUH0037/SIN/08 4.5 1.3 2.1 2.3 0.1 60.3 1.3 0.7 0.6 0.3 0.9 0.7 B5
NUH0043/SIN/08 3.5 2.3 4.8 5.5 1.1 103.6 2.7 0.6 2.2 1.2 0.9 0.7 B5
NUH0047/SIN/08 2.3 0.0 1.9 5.0 2.3 27.5 4.9 1.3 0.5 0.2 1.5 2.2 B5
NUH0049/SIN/08 3.8 1.4 1.7 3.0 0.6 47.0 1.1 0.3 0.8 1.0 0.8 1.4 B5
NUH0083/SIN/08 3.8 0.5 2.5 5.7 1.0 68.6 1.4 0.8 0.8 1.2 0.9 0.9 B5
NUH0085/SIN/08 1.8 1.1 1.5 2.7 1.2 27.2 1.4 0.9 0.7 1.1 0.8 0.8 B5
NUH0086/SIN/08 0.0 1.2 1.2 8.7 0.9 25.4 1.4 0.9 0.5 1.1 0.9 1.8 B5
NUH0013/SIN/08 3.5 2.5 0.8 4.0 1.7 0.2 3.7 151.3 1.2 5.1 0.5 0.7 C2
NUH0075/SIN/08 3.3 2.1 0.8 5.3 1.1 3.9 4.1 160.3 1.3 6.5 1.2 1.2 C2
a The blank control is the background signal obtained with the respective probe in the absence of consensus PCR product. Numbers in boldface accurately identify
the subgenogroups which correlated with the sequencing data of the 11 EV71 reference strains and 11 EV71-positive clinical specimens from the 2008 HFMD outbreak
in Singapore.
b The scrambled probe control was designed with a random or scrambled sequence.
TABLE 2. Mean sample-to-blank control ratios using EV71 subgenogroup-specific probes for determination of assay sensitivitya
Probe Reference strain
Sample-to-blank-control ratio for virus PFU Ratio for no. of plasmid copies
1 5 20 50 100 1 10 100 1,000
A BrCr 0.8 56.1 91.6 174.6
B2 7423/MS/87 3.6 94.1 89.1 207.6
B4 5865/SIN/000009 0.7 1.1 1.3 2.2 12.4
B5 2933-Yamagata-03 2.8 29.4 70.8 76.3
C1 90-3761 18.8 143.3 449.3 511.9
C2 Y97-1188 18.6 103.3 126.5 141.1
C4 75-Yamagata-03 1.4 1.7 4.3 38.5
C5 3437/SIN/06 13.9 94.2 196.5 212.4
B1 2609-AUS-74 0.5 2.1 82.0 223.2
B3 MY104-9-SAR-97 0.6 0.9 63.7 180.2
C3 009-KOR-00 0.9 1.6 11.7 142.4
a The blank control is the background signal obtained with the respective probe in the absence of consensus PCR product. Shown are mean sample-to-blank control
ratios using EV71 subgenogroup-specific probes for the determination of assay sensitivity using reference strains. Numbers in boldface depict the detection limit,
expressed as either the number of virus PFU or the number of plasmid copies.
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melting temperature of 57.5°C, and it yielded a high reading
when a larger viral load was tested for specificity. Therefore,
this apparently lower sensitivity may be due to relatively poorer
amplification efficiency of B4 with the consensus primers. Gel
electrophoresis of amplicons supported this notion, since no
bands were observed with 100 PFU of B4, whereas other sub-
genogroups exhibited bands with 5 or 20 PFU of template
(data not shown). As expected, more virus particles were re-
quired for detection of subgenogroup C4, since the C4 probe
had displayed lower binding activity. One potential limitation
of determining the detection limit using the virus plaque assay
is that it identifies only live virions and may thus overestimate
the sensitivity. The sensitivity of the assay for the B1, B3, and
C3 probes was evaluated using plasmid DNA templates, re-
sulting in a detection limit of at least 100 copies. The use of
plasmid DNA involves fewer steps and variables and may ex-
plain the smaller variations in detection limits between these
three subgenogroups.
In general, we noticed some cross-reactivity between certain
subgenogroups, e.g., with reference strains and viral isolates.
These samples carry relatively higher virus titers or plasmid
copy numbers, which may explain the cross-reactivity, whereas
virtually no cross-reactivity was observed in clinical specimens
that had relatively lower viral loads. Moreover, a mixed infec-
tion is not commonly encountered in clinical settings due to
viral interference that favors one dominant strain. In addition,
despite some cross-reactivity observed for certain reference
strains and viral isolates, the specific ratios were relatively
much higher than nonspecific signals. However, in the titration
experiments, the numbers of viral copies were at relatively low
levels, and thus ratios that were 10-fold greater than the blanks
were considered positive.
In conclusion, the multiplex suspension assay represents a
specific, sensitive, reliable, and high-throughput method for
EV71 detection and subgenogrouping. Its application was
shown to be sensitive enough for clinical specimens and would
greatly facilitate subgenogrouping to enhance epidemiologic
analyses of EV71 infections.
Nucleotide sequence accession numbers. The new VP1 nu-
cleotide sequences were deposited in GenBank under acces-
sion numbers HQ285091 to HQ285109.
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